Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Accumulated Expenses (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Accumulated Expenses for 12 consecutive years, with $3.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses fell 4.5% year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Sep 2025, down 4.5%, and an annual FY2024 reading of $4.3 million, up 3.84% over the prior year.
  • Accumulated Expenses was $3.9 million for Q3 2025 at Lisata Therapeutics, up from $3.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $4.3 million in Q4 2024 and bottomed at $3.2 million in Q1 2025.
  • Average Accumulated Expenses over 3 years is $3.9 million, with a median of $3.9 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses rose 8.25% in 2024, then dropped 21.25% in 2025.
  • Year by year, Accumulated Expenses stood at $4.2 million in 2023, then grew by 3.84% to $4.3 million in 2024, then decreased by 8.78% to $3.9 million in 2025.
  • Business Quant data shows Accumulated Expenses for LSTA at $3.9 million in Q3 2025, $3.5 million in Q2 2025, and $3.2 million in Q1 2025.